In 2023, the treatment success rate for patients treated for multidrug-resistant tuberculosis (MDR-TB) in the UK stood at 84%. Over the forecasted period from 2024 to 2028, there is a projected annual increase in the success rate from 86% to 94%, reflecting an average growth (CAGR) of approximately 2.3% per year.
Trends to watch for future include:
- Enhanced diagnostic tools and treatment methodologies improving MDR-TB outcomes.
- Policy changes and resource allocation towards targeting MDR-TB more effectively.
- Potential challenges from emerging drug-resistant strains that could influence success rates.
